KR100732298B1 - 유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물 - Google Patents

유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물 Download PDF

Info

Publication number
KR100732298B1
KR100732298B1 KR1020050113101A KR20050113101A KR100732298B1 KR 100732298 B1 KR100732298 B1 KR 100732298B1 KR 1020050113101 A KR1020050113101 A KR 1020050113101A KR 20050113101 A KR20050113101 A KR 20050113101A KR 100732298 B1 KR100732298 B1 KR 100732298B1
Authority
KR
South Korea
Prior art keywords
uch
cancer metastasis
ubiquitin
composition
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020050113101A
Other languages
English (en)
Korean (ko)
Other versions
KR20070054952A (ko
Inventor
이공주
김현정
조정우
맹철영
남유경
임상미
김영미
Original Assignee
이화여자대학교 산학협력단
에스케이 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단, 에스케이 주식회사 filed Critical 이화여자대학교 산학협력단
Priority to KR1020050113101A priority Critical patent/KR100732298B1/ko
Priority to EP06843893A priority patent/EP1993581A4/en
Priority to JP2008542245A priority patent/JP2009517381A/ja
Priority to PCT/KR2006/004989 priority patent/WO2007061256A1/en
Priority to US12/094,955 priority patent/US20090208508A1/en
Priority to CNA2006800437290A priority patent/CN101316605A/zh
Publication of KR20070054952A publication Critical patent/KR20070054952A/ko
Application granted granted Critical
Publication of KR100732298B1 publication Critical patent/KR100732298B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
KR1020050113101A 2005-11-24 2005-11-24 유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물 Expired - Fee Related KR100732298B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020050113101A KR100732298B1 (ko) 2005-11-24 2005-11-24 유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물
EP06843893A EP1993581A4 (en) 2005-11-24 2006-11-24 NEW USE OF UBICHITINE C-TERMINAL HYDROLASE-L1
JP2008542245A JP2009517381A (ja) 2005-11-24 2006-11-24 ユビキチンｃ末端ヒドロラーゼ−ｌ１の新規な使用
PCT/KR2006/004989 WO2007061256A1 (en) 2005-11-24 2006-11-24 Novel use of ubiquitin c-terminal hydrolase-l1
US12/094,955 US20090208508A1 (en) 2005-11-24 2006-11-24 Novel use of ubiquitin c-terminal hydrolase-l1
CNA2006800437290A CN101316605A (zh) 2005-11-24 2006-11-24 泛素c末端水解酶l1的新用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050113101A KR100732298B1 (ko) 2005-11-24 2005-11-24 유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물

Publications (2)

Publication Number Publication Date
KR20070054952A KR20070054952A (ko) 2007-05-30
KR100732298B1 true KR100732298B1 (ko) 2007-06-25

Family

ID=38067427

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020050113101A Expired - Fee Related KR100732298B1 (ko) 2005-11-24 2005-11-24 유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물

Country Status (6)

Country Link
US (1) US20090208508A1 (enExample)
EP (1) EP1993581A4 (enExample)
JP (1) JP2009517381A (enExample)
KR (1) KR100732298B1 (enExample)
CN (1) CN101316605A (enExample)
WO (1) WO2007061256A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014185561A1 (ko) * 2013-05-13 2014-11-20 이화여자대학교 산학협력단 신규한 화합물 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 ｕｃｈ－ｌ１ 관련 질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027349A2 (en) * 2007-08-24 2009-03-05 Oryzon Genomics Sa Treatment and prevention of neurodegenerative diseases
WO2010123365A1 (en) * 2009-04-24 2010-10-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Increasing the immunogenicity of epithelial cells infected with human papilloma virus (hpv)
KR101384642B1 (ko) * 2012-06-22 2014-04-22 이화여자대학교 산학협력단 Ｎ―말단이 제거된 유비퀴틴 ｃ―말단 가수분해효소―ｌ１（ｎｔ―ｕｃｈ―ｌ１）를 유효성분으로 포함하는 파킨슨병 예방 및 치료용 약학적 조성물
US20230135030A1 (en) 2018-11-26 2023-05-04 Baseline Global, Inc. Methods, Systems, and a Kit for Diagnosis, Detection, Monitoring & Treatment of Traumatic Brain Injury
CN110684740B (zh) * 2019-08-09 2020-12-08 无锡傲锐东源生物科技有限公司 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用
CN112891542B (zh) * 2021-02-01 2021-11-16 暨南大学 一种包含UCHs抑制剂的药物组合物及其应用
CN113970643B (zh) * 2021-11-23 2023-06-30 北京大学人民医院 检测抗uch-l1表位的自身抗体的试剂在制备sle血清诊断相关产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100520800B1 (ko) 2003-05-19 2005-10-12 김진우 인간 원암유전자 ｐｉｇ２ 및 이에 의해 코드되는 단백질
KR100545076B1 (ko) 2003-01-27 2006-01-24 김현기 인간 원암유전자 ｈｐｐ1 및 이에 의해 코드되는 단백질

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE359515T1 (de) * 1997-02-12 2007-05-15 Electrophoretics Ltd Proteinmarker für lungenkrebs und deren verwendung
US7319010B2 (en) * 2003-05-12 2008-01-15 The Regents Of The University Of Michigan Detection and treatment of cancers of the colon
JP2005272350A (ja) * 2004-03-24 2005-10-06 Vitamin C60 Bioresearch Kk 癌転移阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100545076B1 (ko) 2003-01-27 2006-01-24 김현기 인간 원암유전자 ｈｐｐ1 및 이에 의해 코드되는 단백질
KR100520800B1 (ko) 2003-05-19 2005-10-12 김진우 인간 원암유전자 ｐｉｇ２ 및 이에 의해 코드되는 단백질

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
논문(이화여대 석사학위논문)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014185561A1 (ko) * 2013-05-13 2014-11-20 이화여자대학교 산학협력단 신규한 화합물 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 ｕｃｈ－ｌ１ 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
KR20070054952A (ko) 2007-05-30
EP1993581A1 (en) 2008-11-26
JP2009517381A (ja) 2009-04-30
CN101316605A (zh) 2008-12-03
WO2007061256A1 (en) 2007-05-31
EP1993581A4 (en) 2009-08-05
US20090208508A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
Dorstyn et al. The role of cytochrome c in caspase activation in Drosophila melanogaster cells
JP5628807B2 (ja) リジルｔＲＮＡ合成酵素の細胞内水準を調節して癌転移又は癌細胞の移動を調節する方法
Cicek et al. Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells
JP2002512602A (ja) 増殖性疾患の診断および治療のためのｉａｐ類およびｎａｉｐの検出および調節
KR100732298B1 (ko) 유비키틴 ｃ-말단 가수분해제-ｌ1을 이용한 암전이 진단용조성물
EP1315970B1 (en) Nucleic acid sequence and protein involved in cellular senescence
KR101549245B1 (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료
Ye et al. Knockdown of casein kinase 1E inhibits cell proliferation and invasion of colorectal cancer cells via inhibition of the Wnt/beta-catenin signaling
KR101662062B1 (ko) 코플린-1을 이용한 갈색 지방세포 분화 조절 방법
KR100861464B1 (ko) 발암/전이유전자 ｔｉｐ41과 이에 의해 코드되는 단백질 및이를 이용한 발암 및 전이 진단 키트
KR101128297B1 (ko) Ｔｓｐｙｌ５ 유전자 발현을 억제하여 암세포의 화합물 또는 방사선에 대한 민감도를 증진하는 방법
JP2007282628A (ja) 抗癌剤のスクリーニング方法
RU2449016C2 (ru) Ген, вовлеченный в иммортализацию раковой клетки человека, и его применение
KR20090095304A (ko) 퍼옥시레독신 6의 암 침윤 또는 전이 표적으로서의 용도
KR20160083742A (ko) Emt 저해제 스크리닝 방법
KR20170056146A (ko) Mrs와 cdk4의 결합을 저해하는 항암제 스크리닝 방법
KR101666598B1 (ko) Ndrg2 발현 음성 담낭암 환자에서 mmp-19를 타겟으로 한 담낭암 치료용 약학적 조성물 및 이를 이용한 담낭암의 성장 억제, 전이 억제 및 치료방법
KR101727026B1 (ko) 신규 신경교종의 바이오마커 및 그의 용도
MXPA05000159A (es) Reactivos y metodos para identificar y modular la expresion de genes de senescencia del tumor.
KR20090053225A (ko) 선택적 ｊａｋ 억제제의 고속선별방법
KR101274256B1 (ko) Ｒａｎｉ의 세포사멸 조절제로서의 신규한 용도
WO2006066826A1 (en) Method of diagnosing cancer
WO2006054773A1 (ja) がん細胞の細胞分裂期におけるカスパーゼの活性化と、カスパーゼ阻害物質の抗がん剤などへの利用
Lapi Identification of novel and direct target genes of p73
KR20040079266A (ko) Ｍｉｃ-1 유전자의 억제제를 함유하는 위암 치료제, 위암진단방법 및 진단킷트

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080425

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007322980000

Gazette reference publication date: 20070625

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20121214

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20131128

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20151013

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20161213

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180620

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180620